Brexanolone Patent Expiration

Brexanolone is Used for treating postpartum depression. It was first introduced by Sage Therapeutics Inc in its drug Zulresso on Jun 17, 2019.


Brexanolone Patents

Given below is the list of patents protecting Brexanolone, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Zulresso US10117951 Sulfoalkyl ether cyclodextrin compositions Mar 13, 2029 Sage Therap
Zulresso US10251894 Anticonvulsant activity of steroids Nov 27, 2033 Sage Therap
Zulresso US10322139 Neuroactive steroid formulations and methods of treating CNS disorders Jan 23, 2033 Sage Therap
Zulresso US10940156 Neuroactive steroids, compositions, and uses thereof Mar 08, 2037 Sage Therap
Zulresso US7635773 Sulfoalkyl ether cyclodextrin compositions Mar 13, 2029 Sage Therap
Zulresso US8410077 Sulfoalkyl ether cyclodextrin compositions Mar 13, 2029 Sage Therap
Zulresso US9200088 Sulfoalkyl ether cyclodextrin compositions Mar 13, 2029 Sage Therap
Zulresso US9750822 Sulfoalkyl ether cyclodextrin compositions Mar 13, 2029 Sage Therap


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Brexanolone's patents.

Given below is the list recent legal activities going on the following patents of Brexanolone.

Event Date Patent/Publication
Patent litigations
Payment of Maintenance Fee, 4th Year, Large Entity 30 Nov, 2022 US10322139
Payment of Maintenance Fee, 4th Year, Large Entity 21 Sep, 2022 US10251894
Patent Issue Date Used in PTA Calculation 09 Mar, 2021 US10940156
Recordation of Patent Grant Mailed 09 Mar, 2021 US10940156
Email Notification 18 Feb, 2021 US10940156
Issue Notification Mailed 17 Feb, 2021 US10940156
Dispatch to FDC 29 Jan, 2021 US10940156
Email Notification 18 Jan, 2021 US10940156
Mail Response to 312 Amendment (PTO-271) 18 Jan, 2021 US10940156
Response to Amendment under Rule 312 13 Jan, 2021 US10940156



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳